Fund Holdings — Lion Point Capital, LP

Total Portfolio Value:
$17.26M
Total Bought:
$0
Total Sold:
$610.2K
Net Transaction:
-$610.2K
Notable People:
Carl Didric Marcus Cederholm
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Cue Biopharma, Inc.(CUE)52,92852,9280$1.67M$1.37M7.93%-$301.2K
Praxis Precision Medicines, Inc.(PRAX)4,4504,4500$1.49M$1.30M7.51%-$193.8K
Royalty Pharma plcCL A(RPRX)21,40021,4000$1.20M$1.25M7.24%+$49.0K
Fennec Pharmaceuticals Inc.(FENC)112,434112,4340$1.21M$1.20M6.94%-$11.2K
COMPASS Pathways plcADS(CMPS)80,00080,0000$1.13M$995.2K5.77%-$136.8K
MoonLake ImmunotherapeuticsCL A(MLTX)67,50067,5000$1.31M$789.8K4.58%-$524.5K
Geron Corporation(GERN)578,000578,0000$739.8K$710.9K4.12%-$28.9K
Milestone Pharmaceuticals Inc.(MIST)820,000820,0000$1.10M$709.9K4.11%-$388.9K
Biohaven Ltd.(BHVN)51,70051,7000$769.3K$690.2K4.00%-$79.1K
Syndax Pharmaceuticals, Inc.(SNDX)36,00036,0000$787.0K$676.8K3.92%-$110.2K
Benitec Biopharma Inc.(BNTC)62,00062,0000$829.6K$620.0K3.59%-$209.6K
Disc Medicine, Inc.(IRON)8,1008,1000$592.4K$530.2K3.07%-$62.2K
Sarepta Therapeutics, Inc.(SRPT)28,50028,5000$512.1K$519.3K3.01%+$7.1K
Kura Oncology, Inc.(KURA)46,00046,0000$504.6K$492.7K2.85%-$12.0K
Viatris Inc.(VTRS)27,70027,7000$439.9K$490.8K2.84%+$51.0K
Ardelyx Inc128,650128,6500$656.1K$440.0K2.55%-$216.1K
Edgewise Therapeutics, Inc.(EWTX)9,1009,1000$369.7K$369.5K2.14%-$273
uniQure N.V.SHS(QURE)14,70014,7000$677.1K$355.2K2.06%-$321.9K
Azenta, Inc.(AZTA)9,7009,7000$247.5K$338.4K1.96%+$90.9K
Pacira BioSciences, Inc.(PCRX)13,50013,5000$342.5K$338.2K1.96%-$4.3K
Humacyte, Inc.(HUMA)650,000650,0000$507.3K$336.5K1.95%-$170.8K
BridgeBio Pharma, Inc.(BBIO)5,0005,0000$372.4K$329.0K1.91%-$43.4K
Janux Therapeutics, Inc.(JANX)19,00019,0000$291.8K$328.3K1.90%+$36.5K
Dyne Therapeutics, Inc.(DYN)18,00018,0000$399.8K$290.0K1.68%-$109.8K
Jasper Therapeutics, Inc.(JSPR)465,000465,0000$195.8K$269.7K1.56%+$73.9K
Mineralys Therapeutics, Inc.(MLYS)10,50010,5000$283.3K$263.9K1.53%-$19.4K
GH Research PLC(GHRS)10,20010,2000$274.2K$239.5K1.39%-$34.7K
Rocket Pharmaceuticals, Inc.(RCKT)86,00086,0000$294.1K$226.2K1.31%-$67.9K
REGENXBIO Inc.(RGNX)26,60026,6000$318.7K$200.3K1.16%-$118.4K
Innoviva, Inc.(INVA)8,2008,2000$186.2K$173.9K1.01%-$12.3K
Arcutis Biotherapeutics, Inc.(ARQT)5,2505,2500$137.7K$138.8K0.80%+$1.1K
Innate Pharma S.A.ADS(IPHA)81,15181,1510$149.3K$132.3K0.77%-$17.0K
Seres Therapeutics, Inc.(MCRB)31,57031,5700$249.1K$105.8K0.61%-$143.3K
Spruce Biosciences Inc1,0001,0000$54.0K$48.6K0.28%-$5.4K
Lantheus Holdings, Inc.(LNTH)5,5000-5,500$610.2K$0—-$610.2K
Page 1 of 1
Lion Point Capital, LP — 13F Holdings — Q3 2026 | TickerTrail